Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H G Bone

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Bone|April 20, 2010
Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral densityH K Genant, K Engelke, D A Hanley, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 26, 2000
Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of boneP Bianco, M Riminucci, A Majolagbe, et al.
The Journal of Clinical Endocrinology and Metabolism|September 22, 2000
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study GroupR P Tonino, P J Meunier, R Emkey, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 29, 2014
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonateJ P Brown, C Roux, P R Ho, et al.
The Journal of Clinical Endocrinology and Metabolism|January 1, 1997
Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study CentersH G Bone, R W Downs, J R Tucci, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 7, 2009
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone massD L Kendler, L Bessette, C D Hill, et al.
The Journal of Clinical Endocrinology and Metabolism|June 9, 2016
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral BisphosphonatesP D Miller, N Pannacciulli, J P Brown, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 30, 2014
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture TrialH G Bone, D W Dempster, J A Eisman, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|September 12, 2015
Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture TrialH G Bone, D W Dempster, J A Eisman, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|July 27, 2006
[Diagnosis and therapy of sepsis]K Reinhart, F M Brunkhorst, H-G Bone, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Bone|April 20, 2010
Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral densityH K Genant, K Engelke, D A Hanley, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 26, 2000
Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of boneP Bianco, M Riminucci, A Majolagbe, et al.
The Journal of Clinical Endocrinology and Metabolism|September 22, 2000
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study GroupR P Tonino, P J Meunier, R Emkey, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 29, 2014
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonateJ P Brown, C Roux, P R Ho, et al.
The Journal of Clinical Endocrinology and Metabolism|January 1, 1997
Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study CentersH G Bone, R W Downs, J R Tucci, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 7, 2009
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone massD L Kendler, L Bessette, C D Hill, et al.
The Journal of Clinical Endocrinology and Metabolism|June 9, 2016
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral BisphosphonatesP D Miller, N Pannacciulli, J P Brown, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 30, 2014
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture TrialH G Bone, D W Dempster, J A Eisman, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|September 12, 2015
Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture TrialH G Bone, D W Dempster, J A Eisman, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|July 27, 2006
[Diagnosis and therapy of sepsis]K Reinhart, F M Brunkhorst, H-G Bone, et al.
Pageof 9